The total return over the past 12 months is -47.92% vs. +16.94% for the S&P 500. So far it's up -30.64% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (47.92%) | (30.29%) | (52.67%) | (35.88%) | N/A | N/A |
| Total Return CAGR | (47.92%) | (30.29%) | (52.67%) | (35.88%) | N/A | N/A |
| Revenue CAGR | N/A | (67.17%) | (51.49%) | (29.92%) | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Kyntra Bio, Inc. (KYNB)
| Year | Start price | End price | KYNB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.78 | $6.09 | (30.64%) | +14.51% | (45.15%) |
| 2025 | $13.25 | $8.78 | (33.74%) | +17.72% | (51.46%) |
| 2024 | $22.15 | $13.25 | (40.18%) | +24.89% | (65.07%) |
| 2023 | $400.50 | $22.15 | (94.47%) | +26.19% | (120.66%) |
| 2022 | $352.50 | $400.50 | +13.62% | (18.17%) | +31.79% |
| 2021 | $927.25 | $352.50 | (61.98%) | +28.74% | (90.72%) |
| 2020 | $1,072.25 | $927.25 | (13.52%) | +18.37% | (31.89%) |
| 2019 | $1,157.00 | $1,072.25 | (7.32%) | +31.22% | (38.54%) |
| 2018 | $1,185.00 | $1,157.00 | (2.36%) | (4.56%) | +2.20% |
| 2017 | $535.00 | $1,185.00 | +121.50% | +21.70% | +99.80% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
